Kymera Therapeutics Inc (KYMR) returns
Kymera Therapeutics returns over 5 years
$1,000 invested in Kymera Therapeutics five years ago was worth $2,151 at the close on October 30, 2026, with dividends reinvested: an average return of 16.6% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | +13.3% | — | $1,133 | -0.9% |
| 3 months | +18.3% | — | $1,183 | +2.1% |
| Year to date | +62.7% | — | $1,627 | +11.7% |
| 1 year | +106.1% | — | $2,061 | +12.4% |
| 3 years | +1,029% | +124.3% | $11,286 | +88.5% |
| 5 years | +115.1% | +16.6% | $2,151 | +76.0% |
Kymera Therapeutics return by calendar year
| Year | KYMR | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | +62.7% | +11.7% | +51.1% |
| 2025 | +93.4% | +17.7% | +75.7% |
| 2024 | +58.0% | +24.9% | +33.1% |
| 2023 | +2.0% | +26.2% | -24.2% |
| 2022 | -60.7% | -18.2% | -42.5% |
| 2021 | +2.4% | +28.7% | -26.3% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: KYMR financials
No forecast, no recommendation. This page describes Kymera Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.